Review



sensiscreen ® egfr liquid assay platform  (PentaBase)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    PentaBase sensiscreen ® egfr liquid assay platform
    Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA <t>EGFR</t> analyses.
    Sensiscreen ® Egfr Liquid Assay Platform, supplied by PentaBase, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sensiscreen ® egfr liquid assay platform/product/PentaBase
    Average 90 stars, based on 1 article reviews
    sensiscreen ® egfr liquid assay platform - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies"

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0253687

    Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA EGFR analyses.
    Figure Legend Snippet: Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA EGFR analyses.

    Techniques Used:

    PCR curves obtained when challenging assays with cell lines or plasmids containing the indicated EGFR mutations. Plasmids were diluted 1:1 in WT gDNA to ensure a total template amount of 1600 copies. Reference assay PCR curves are represented by heavy coloured lines and mutation specific assay PCR curves by light coloured lines as indicated in figure legends. Abbreviations: Ct, Cycle threshold; EGFR, Epidermal growth factor receptor.
    Figure Legend Snippet: PCR curves obtained when challenging assays with cell lines or plasmids containing the indicated EGFR mutations. Plasmids were diluted 1:1 in WT gDNA to ensure a total template amount of 1600 copies. Reference assay PCR curves are represented by heavy coloured lines and mutation specific assay PCR curves by light coloured lines as indicated in figure legends. Abbreviations: Ct, Cycle threshold; EGFR, Epidermal growth factor receptor.

    Techniques Used: Mutagenesis

    A. Histograms showing the frequency and distribution of mutant copies detected in 102 replicates for assays. B. Boxplot showing the collectively recovered number of copies by the three assays and thereby the overall detected copy number by assays. Abbreviations: EGFR, Epidermal growth factor receptor.
    Figure Legend Snippet: A. Histograms showing the frequency and distribution of mutant copies detected in 102 replicates for assays. B. Boxplot showing the collectively recovered number of copies by the three assays and thereby the overall detected copy number by assays. Abbreviations: EGFR, Epidermal growth factor receptor.

    Techniques Used: Mutagenesis

    Repeatability and accuracy evaluation of SensiScreen ® EGFR Liquid assays: Number of copies mutated for Exon 19 deletion, T790M or L858R.
    Figure Legend Snippet: Repeatability and accuracy evaluation of SensiScreen ® EGFR Liquid assays: Number of copies mutated for Exon 19 deletion, T790M or L858R.

    Techniques Used:

    Graphs describing the LoB evaluation based on the characterization of repeated testing of cfDNA pooled from 58 healthy donors A. Curves representing the T790M LoB results. B. Curves representing the L858R LoB results. C. Curves representing the EGFR exon 19 deletion LoB results.
    Figure Legend Snippet: Graphs describing the LoB evaluation based on the characterization of repeated testing of cfDNA pooled from 58 healthy donors A. Curves representing the T790M LoB results. B. Curves representing the L858R LoB results. C. Curves representing the EGFR exon 19 deletion LoB results.

    Techniques Used:

    Overview of the EGFR phenotypes detected by the Therascreen ® (QIAGEN) versus SensiScreen ® EGFR Liquid assay (Pentabase) and IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific) using cohort I and agreement or disagreement between platforms (N = 34).
    Figure Legend Snippet: Overview of the EGFR phenotypes detected by the Therascreen ® (QIAGEN) versus SensiScreen ® EGFR Liquid assay (Pentabase) and IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific) using cohort I and agreement or disagreement between platforms (N = 34).

    Techniques Used:

    Overview of the EGFR phenotypes detected by the SensiScreen ® EGFR Liquid assay (PentaBase ApS) versus the ctEGFR Mutation Detection Kit (EntroGen) using cohort II and agreement or disagreement between platforms (N = 34).
    Figure Legend Snippet: Overview of the EGFR phenotypes detected by the SensiScreen ® EGFR Liquid assay (PentaBase ApS) versus the ctEGFR Mutation Detection Kit (EntroGen) using cohort II and agreement or disagreement between platforms (N = 34).

    Techniques Used: Mutagenesis



    Similar Products

    sensiscreen ® egfr liquid assay platform  (PentaBase)
    90
    PentaBase sensiscreen ® egfr liquid assay platform
    Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA <t>EGFR</t> analyses.
    Sensiscreen ® Egfr Liquid Assay Platform, supplied by PentaBase, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sensiscreen ® egfr liquid assay platform/product/PentaBase
    Average 90 stars, based on 1 article reviews
    sensiscreen ® egfr liquid assay platform - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    sensiscreen® egfr liquid assay platform  (PentaBase)
    90
    PentaBase sensiscreen® egfr liquid assay platform
    Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA <t>EGFR</t> analyses.
    Sensiscreen® Egfr Liquid Assay Platform, supplied by PentaBase, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sensiscreen® egfr liquid assay platform/product/PentaBase
    Average 90 stars, based on 1 article reviews
    sensiscreen® egfr liquid assay platform - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA EGFR analyses.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA EGFR analyses.

    Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

    Techniques:

    PCR curves obtained when challenging assays with cell lines or plasmids containing the indicated EGFR mutations. Plasmids were diluted 1:1 in WT gDNA to ensure a total template amount of 1600 copies. Reference assay PCR curves are represented by heavy coloured lines and mutation specific assay PCR curves by light coloured lines as indicated in figure legends. Abbreviations: Ct, Cycle threshold; EGFR, Epidermal growth factor receptor.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: PCR curves obtained when challenging assays with cell lines or plasmids containing the indicated EGFR mutations. Plasmids were diluted 1:1 in WT gDNA to ensure a total template amount of 1600 copies. Reference assay PCR curves are represented by heavy coloured lines and mutation specific assay PCR curves by light coloured lines as indicated in figure legends. Abbreviations: Ct, Cycle threshold; EGFR, Epidermal growth factor receptor.

    Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

    Techniques: Mutagenesis

    A. Histograms showing the frequency and distribution of mutant copies detected in 102 replicates for assays. B. Boxplot showing the collectively recovered number of copies by the three assays and thereby the overall detected copy number by assays. Abbreviations: EGFR, Epidermal growth factor receptor.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: A. Histograms showing the frequency and distribution of mutant copies detected in 102 replicates for assays. B. Boxplot showing the collectively recovered number of copies by the three assays and thereby the overall detected copy number by assays. Abbreviations: EGFR, Epidermal growth factor receptor.

    Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

    Techniques: Mutagenesis

    Repeatability and accuracy evaluation of SensiScreen ® EGFR Liquid assays: Number of copies mutated for Exon 19 deletion, T790M or L858R.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Repeatability and accuracy evaluation of SensiScreen ® EGFR Liquid assays: Number of copies mutated for Exon 19 deletion, T790M or L858R.

    Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

    Techniques:

    Graphs describing the LoB evaluation based on the characterization of repeated testing of cfDNA pooled from 58 healthy donors A. Curves representing the T790M LoB results. B. Curves representing the L858R LoB results. C. Curves representing the EGFR exon 19 deletion LoB results.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Graphs describing the LoB evaluation based on the characterization of repeated testing of cfDNA pooled from 58 healthy donors A. Curves representing the T790M LoB results. B. Curves representing the L858R LoB results. C. Curves representing the EGFR exon 19 deletion LoB results.

    Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

    Techniques:

    Overview of the EGFR phenotypes detected by the Therascreen ® (QIAGEN) versus SensiScreen ® EGFR Liquid assay (Pentabase) and IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific) using cohort I and agreement or disagreement between platforms (N = 34).

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Overview of the EGFR phenotypes detected by the Therascreen ® (QIAGEN) versus SensiScreen ® EGFR Liquid assay (Pentabase) and IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific) using cohort I and agreement or disagreement between platforms (N = 34).

    Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

    Techniques:

    Overview of the EGFR phenotypes detected by the SensiScreen ® EGFR Liquid assay (PentaBase ApS) versus the ctEGFR Mutation Detection Kit (EntroGen) using cohort II and agreement or disagreement between platforms (N = 34).

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Overview of the EGFR phenotypes detected by the SensiScreen ® EGFR Liquid assay (PentaBase ApS) versus the ctEGFR Mutation Detection Kit (EntroGen) using cohort II and agreement or disagreement between platforms (N = 34).

    Article Snippet: In our setup, the SensiScreen ® EGFR Liquid assay platform (PentaBase) outperformed the Therascreen ® platform (Qiagen) and showed 100% agreement at the sequence level to the IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific).

    Techniques: Mutagenesis

    Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA EGFR analyses.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Median age was 65.5 years for cohort I and 69.5 years for cohort II at the time of routine ctDNA EGFR analyses.

    Article Snippet: This motivated us to evaluate the newly developed and commercially available SensiScreen ® EGFR Liquid assay platform (PentaBase) with regard to sensitivity, linearity, repeatability and accuracy and finally to compare it to our already implemented methods.

    Techniques:

    PCR curves obtained when challenging assays with cell lines or plasmids containing the indicated EGFR mutations. Plasmids were diluted 1:1 in WT gDNA to ensure a total template amount of 1600 copies. Reference assay PCR curves are represented by heavy coloured lines and mutation specific assay PCR curves by light coloured lines as indicated in figure legends. Abbreviations: Ct, Cycle threshold; EGFR, Epidermal growth factor receptor.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: PCR curves obtained when challenging assays with cell lines or plasmids containing the indicated EGFR mutations. Plasmids were diluted 1:1 in WT gDNA to ensure a total template amount of 1600 copies. Reference assay PCR curves are represented by heavy coloured lines and mutation specific assay PCR curves by light coloured lines as indicated in figure legends. Abbreviations: Ct, Cycle threshold; EGFR, Epidermal growth factor receptor.

    Article Snippet: This motivated us to evaluate the newly developed and commercially available SensiScreen ® EGFR Liquid assay platform (PentaBase) with regard to sensitivity, linearity, repeatability and accuracy and finally to compare it to our already implemented methods.

    Techniques: Mutagenesis

    A. Histograms showing the frequency and distribution of mutant copies detected in 102 replicates for assays. B. Boxplot showing the collectively recovered number of copies by the three assays and thereby the overall detected copy number by assays. Abbreviations: EGFR, Epidermal growth factor receptor.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: A. Histograms showing the frequency and distribution of mutant copies detected in 102 replicates for assays. B. Boxplot showing the collectively recovered number of copies by the three assays and thereby the overall detected copy number by assays. Abbreviations: EGFR, Epidermal growth factor receptor.

    Article Snippet: This motivated us to evaluate the newly developed and commercially available SensiScreen ® EGFR Liquid assay platform (PentaBase) with regard to sensitivity, linearity, repeatability and accuracy and finally to compare it to our already implemented methods.

    Techniques: Mutagenesis

    Repeatability and accuracy evaluation of SensiScreen ® EGFR Liquid assays: Number of copies mutated for Exon 19 deletion, T790M or L858R.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Repeatability and accuracy evaluation of SensiScreen ® EGFR Liquid assays: Number of copies mutated for Exon 19 deletion, T790M or L858R.

    Article Snippet: This motivated us to evaluate the newly developed and commercially available SensiScreen ® EGFR Liquid assay platform (PentaBase) with regard to sensitivity, linearity, repeatability and accuracy and finally to compare it to our already implemented methods.

    Techniques:

    Graphs describing the LoB evaluation based on the characterization of repeated testing of cfDNA pooled from 58 healthy donors A. Curves representing the T790M LoB results. B. Curves representing the L858R LoB results. C. Curves representing the EGFR exon 19 deletion LoB results.

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Graphs describing the LoB evaluation based on the characterization of repeated testing of cfDNA pooled from 58 healthy donors A. Curves representing the T790M LoB results. B. Curves representing the L858R LoB results. C. Curves representing the EGFR exon 19 deletion LoB results.

    Article Snippet: This motivated us to evaluate the newly developed and commercially available SensiScreen ® EGFR Liquid assay platform (PentaBase) with regard to sensitivity, linearity, repeatability and accuracy and finally to compare it to our already implemented methods.

    Techniques:

    Overview of the EGFR phenotypes detected by the Therascreen ® (QIAGEN) versus SensiScreen ® EGFR Liquid assay (Pentabase) and IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific) using cohort I and agreement or disagreement between platforms (N = 34).

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Overview of the EGFR phenotypes detected by the Therascreen ® (QIAGEN) versus SensiScreen ® EGFR Liquid assay (Pentabase) and IOT ® Oncomine cell-free nucleic acids assay (Thermo Fisher Scientific) using cohort I and agreement or disagreement between platforms (N = 34).

    Article Snippet: This motivated us to evaluate the newly developed and commercially available SensiScreen ® EGFR Liquid assay platform (PentaBase) with regard to sensitivity, linearity, repeatability and accuracy and finally to compare it to our already implemented methods.

    Techniques:

    Overview of the EGFR phenotypes detected by the SensiScreen ® EGFR Liquid assay (PentaBase ApS) versus the ctEGFR Mutation Detection Kit (EntroGen) using cohort II and agreement or disagreement between platforms (N = 34).

    Journal: PLoS ONE

    Article Title: A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies

    doi: 10.1371/journal.pone.0253687

    Figure Lengend Snippet: Overview of the EGFR phenotypes detected by the SensiScreen ® EGFR Liquid assay (PentaBase ApS) versus the ctEGFR Mutation Detection Kit (EntroGen) using cohort II and agreement or disagreement between platforms (N = 34).

    Article Snippet: This motivated us to evaluate the newly developed and commercially available SensiScreen ® EGFR Liquid assay platform (PentaBase) with regard to sensitivity, linearity, repeatability and accuracy and finally to compare it to our already implemented methods.

    Techniques: Mutagenesis